Assignee
NBE THERAPEUTICS AG
CH·16 granted patents·5 pending applications·81 citations·filing 2014–2022
Top patents by PatentIndex Score
21 records- 0197US11364301B2Method of producing an immunoligand/payload conjugateNBE THERAPEUTICS AG·Filed 2020·Granted Jun 21, 2022·6 cites·20 claims
- 0296US11242388B2ROR1 antibody compositions and related methodsNBE THERAPEUTICS AG·Filed 2020·Granted Feb 8, 2022·8 cites·12 claims
- 0396US10864277B2Method of producing an immunoligand/payload conjugateNBE THERAPEUTICS AG·Filed 2017·Granted Dec 15, 2020·13 cites·36 claims
- 0494US10960083B2Binding protein drug conjugates comprising anthracycline derivativesNBE THERAPEUTICS AG·Filed 2019·Granted Mar 30, 2021·6 cites·13 claims
- 0593US10618959B2ROR1 antibody compositions and related methodsNBE THERAPEUTICS AG·Filed 2018·Granted Apr 14, 2020·11 cites·26 claims
- 0693US9872923B2Method of producing an immunoligand/payload conjugateNBE THERAPEUTICS AG·Filed 2014·Granted Jan 23, 2018·19 cites·14 claims
- 0789US10758556B2Anthracycline-based antibody drug conjugates having high in vivo tolerabilityNBE THERAPEUTICS AG·Filed 2019·Granted Sep 1, 2020·8 cites·31 claims
- 0885US10517959B2Binding protein drug conjugates comprising anthracycline derivativesNBE THERAPEUTICS AG·Filed 2018·Granted Dec 31, 2019·3 cites·8 claims
- 0985US10188745B2Binding protein drug conjugates comprising anthracycline derivativesNBE THERAPEUTICS AG·Filed 2015·Granted Jan 29, 2019·4 cites·28 claims
- 1082US11447546B2Human antibodies binding to ROR2NBE THERAPEUTICS AG·Filed 2018·Granted Sep 20, 2022·2 cites·5 claims
- 1180US11986535B2Method of producing an immunoligand/payload conjugateNBE THERAPEUTICS AG·Filed 2022·Granted May 21, 2024·0 cites·23 claims
- 1274US11833120B2Binding protein drug conjugates comprising anthracycline derivativesNBE THERAPEUTICS AG·Filed 2021·Granted Dec 5, 2023·0 cites·18 claims
- 1370US2022153839A1Ror1 antibody compositions and related methodsNBE THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 1469US12533420B2Sortase F and its use in methods for conjugationNBE THERAPEUTICS AG·Filed 2019·Granted Jan 27, 2026·1 cites·13 claims
- 1566US12275789B2Human antibodies binding to ROR2NBE THERAPEUTICS AG·Filed 2022·Granted Apr 15, 2025·0 cites·9 claims
- 1658US12121527B2Anthracycline-based antibody drug conjugates having high in vivo tolerabilityNBE THERAPEUTICS AG·Filed 2020·Granted Oct 22, 2024·0 cites·19 claims
- 1751US2021379194A1Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applicationsNBE THERAPEUTICS AG·Filed 2019·Application pending·0 cites
- 1847US2021139579A1Multispecific antibody product that binds to different ror1 epitopesNBE THERAPEUTICS AG·Filed 2018·Application pending·0 cites
- 1944US11845793B2Anti-ROR1 antibodiesNBE THERAPEUTICS AG·Filed 2016·Granted Dec 19, 2023·0 cites·8 claims
- 2036US2018028682A1Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugationNBE THERAPEUTICS AG·Filed 2016·Application pending·0 cites
- 2136US2019112385A1Anti-mesothelin antibodiesNBE THERAPEUTICS AG·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when NBE THERAPEUTICS AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →